Cosmetic cross-reference Noindex: medium evidence

48145-04-6

CAS 48145-04-6

48145-04-6 (CAS 48145-04-6) is a pharmaceutical compound with 1 bioactivity target and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
1
SOURCE DrugCentral
Adverse signals
0
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
48145-04-6
CAS Number
48145-04-6
UNII
N95C96I48M
InChIKey
RZVINYQDSSQUKO-UHFFFAOYSA-N
ChEMBL ID
CHEMBL1596010
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE EMBL-EBI ChEMBL 1 bioactivity row

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- Potency 71985.65000000001 nM 6 -
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is 48145-04-6 used for in pharmaceutical contexts?

48145-04-6 (CAS 48145-04-6) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for 48145-04-6?

No adverse-event association or SIDER side-effect rows are rendered for 48145-04-6 in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is 48145-04-6 also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Phenoxyethyl Acrylate with EU status "permitted".

What clinical phase is 48145-04-6 in?

No phase 1-4 clinical development badge is rendered for 48145-04-6 because the matched compound identifier rows do not contain a max-phase value.